Advertisement
Advertisement
NMRA
Neumora Therapeutics, Inc. Common Stock
2.00
USDSponsored
-0.09
-4.55%
Apr 02, 15:56 UTC -4
Closed
After-Market
2.00
0.00
+0.25%
NMRA Earnings Reports
Positive Surprise Ratio
NMRA beat 5 of 10 last estimates.
50%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.31
Implied change from Q4 25 (Revenue/ EPS)
--
/-11.43%
Implied change from Q1 25 (Revenue/ EPS)
--
/-26.19%
Neumora Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 30, 2026, NMRA reported earnings of -0.35 USD per share (EPS) for Q4 25, missing the estimate of -0.33 USD, resulting in a -5.39% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.53% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.31 USD, with revenue projected to reach -- USD, implying an decrease of -11.43% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nanobiotix S.A. - ADR
Report Date
Mar 31, 2026 For Q4 25
Estimate
$0.55
Actual
-$0.39
Surprise
-170.16%
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
Cyclerion Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.38
Actual
-$0.21
Surprise
+45.82%
Femasys Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.80%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$2.02
Surprise
-68.69%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.16
Surprise
+34.64%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Neumora Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.35, missing estimates by -5.39%, and revenue of $0.00, 0% as expectations.
How did the market react to Neumora Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 3.53%, changed from $3.26 before the earnings release to $3.38 the day after.
When is Neumora Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Neumora Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement